AAE Guidance on the Use of Systemic Antibiotics in Endodontics
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al. -
Novel Antimicrobial Agents Inhibiting Lipid II Incorporation Into Peptidoglycan Essay MBB
27 -7-2019 Novel antimicrobial agents inhibiting lipid II incorporation into peptidoglycan Essay MBB Mark Nijland S3265978 Supervisor: Prof. Dr. Dirk-Jan Scheffers Molecular Microbiology University of Groningen Content Abstract..............................................................................................................................................2 1.0 Peptidoglycan biosynthesis of bacteria ........................................................................................3 2.0 Novel antimicrobial agents ...........................................................................................................4 2.1 Teixobactin ...............................................................................................................................4 2.2 tridecaptin A1............................................................................................................................7 2.3 Malacidins ................................................................................................................................8 2.4 Humimycins ..............................................................................................................................9 2.5 LysM ........................................................................................................................................ 10 3.0 Concluding remarks .................................................................................................................... 11 4.0 references ................................................................................................................................. -
Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
Brilacidin First-in-Class Defensin-Mimetic Drug Candidate Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment April 20, 2020 Page # I. Brilacidin: Background Information 2 II. Brilacidin: Two Primary Mechanisms of Action 3 Membrane Disruption 4 Immunomodulatory 7 III. Brilacidin: Several Complementary Ways of Targeting COVID-19 10 Antiviral (anti-SARS-CoV-2 activity) 11 Immuno/Anti-Inflammatory 13 Antimicrobial 16 IV. Brilacidin: COVID-19 Clinical Development Pathways 18 Drug 18 Vaccine 20 Next Steps 24 V. Brilacidin: Phase 2 Clinical Trial Data in Other Indications 25 VI. AMPs/Defensins (Mimetics): Antiviral Properties 30 VII. AMPs/Defensins (Mimetics): Anti-Coronavirus Potential 33 VIII. The Broader Context: Characteristics of the COVID-19 Pandemic 36 Innovation Pharmaceuticals 301 Edgewater Place, Ste 100 Wakefield, MA 01880 978.921.4125 [email protected] Innovation Pharmaceuticals: Mechanism of Action, Pre/Clinical Data and Academic Literature Supporting the Development of Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (April 20, 2020) Page 1 of 45 I. Brilacidin: Background Information Brilacidin (PMX-30063) is Innovation Pharmaceutical’s lead Host Defense Protein (HDP)/Defensin-Mimetic drug candidate targeting SARS-CoV-2, the virus responsible for COVID-19. Laboratory testing conducted at a U.S.-based Regional Biocontainment Laboratory (RBL) supports Brilacidin’s antiviral activity in directly inhibiting SARS-CoV-2 in cell-based assays. Additional pre-clinical and clinical data support Brilacidin’s therapeutic potential to inhibit the production of IL-6, IL-1, TNF- and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), identified as central drivers in the worsening prognoses of COVID-19 patients. -
Which Antibiotic Prophylaxis Guidelines for Infective Endocarditis Should Canadian Dentists Follow?
Debate & O P I N I O N Which Antibiotic Prophylaxis Guidelines for Infective Endocarditis Should Canadian Dentists Follow? Contact Author Herve Y. Sroussi, DMD, PhD; Ashwin R. Prabhu, BDS; Dr. Epstein Joel B. Epstein, DMD, MSD, FRCD(C) Email: [email protected] For citation purposes, the electronic version is the definitive version of this article: www.cda-adc.ca/jcda/vol-73/issue-5/401.html ental providers must keep up to date 2 weeks following a procedure, dental proced- with antibiotic prophylaxis guidelines ures conducted even months earlier may be Dfor infectious endocarditis (IE) as these questioned as causative of IE.4 Furthermore, guidelines represent standards of care and periodontal and dental disease increase the determine medicolegal standards. A survey risk of bacteremia with activities of daily of Canadian dentists revealed that practi- living and may more commonly cause bac- tioners tend to employ antibiotic prophylaxis teremia; therefore, good oral care is of para- according to the guidelines in place at the mount importance in patients with conditions time of their graduation from dental school that place them at risk for IE. — guidelines that often do not meet the cur- To reduce the risk of IE following dental rent standards,1 as both the American Heart procedures, prophylactic measures have Association (AHA)2 and the British Society been developed by experts in the fields of for Antimicrobial Chemotherapy (BSAC)3 have microbiology, epidemiology, cardiology and currently updated their recommendations. dentistry. The principle preventive measure Host factors that increase the risk of IE recommended is the use of prophylactic anti- include specific cardiac abnormalities, a biotics before certain dental procedures in pa- previous episode of IE and the extent of the tients identified as at risk. -
Penicillin Allergy Guidance Document
Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment. -
Antibiotic Prophylaxis for Surgical Procedures
Summary and Conclusions Antibiotic Prophylaxis for Surgical Procedures A Systematic Review Swedish Council on Health Technology Assessment SBU Board of Directors and Scientific Advisory Committee Secretariat MÅNS ROSÉN Executive Director, SBU Board of Directors NINA REHNQVIST BJÖRN KLINGE MARGARETA TROEIN Karolinska Institute, Solna Karolinska Institute, TÖLLBORN (Chair) Solna The Swedish Society of Medicine EVA NILSSON BÅGENHOLM MÅNS ROSÉN The Swedish Medical SBU MATS ULFENDAHL Association The Swedish Research KARIN STRANDBERG NÖJD Council HÅKAN CEDER The Swedish Association The National Board of Local Authorities and SABINA WIKGREN ORSTAM of Health and Welfare Regions The Swedish Association ANNA-KARIN EKLUND HÅKAN SÖRMAN of Local Authorities and Swedish Association The Swedish Association Regions of Health Professionals of Local Authorities and Regions Scientific Advisory Committee DAVID BERGQVIST MATS G HANSSON ULF NÄSLUND Uppsala University Uppsala University Norrland University Hospital (Chair) Hospital, Umeå MIKAEL HELLSTRÖM BJÖRN BEERMANN Sahlgrenska Hospital, JOAKIM RAMSBERG Medical Products Agency, Gothenburg i3 Innovus, Stockholm Uppsala MARGARETA MÖLLER BO RUNESON CHRISTINA BERGH University Hospital, Karolinska Institute, Sahlgrenska Hospital, Örebro Solna Gothenburg JÖRGEN NORDENSTRÖM GUNNEL SVENSÄTER CECILIA BJÖRKELUND Karolinska University Malmö University Gothenburg University Hospital, Solna ANIA WILLMAN 2 SBU'S SUMMARY AND CONCLUSIONS SÖLVE ELMSTÅHL OLOF NYRÉN Blekinge Institute of University Hospital, Karolinska Institute, -
Guideline on Antibiotic Prophylaxis for Dental Patients at Risk for Infection
american academy of pediatric dentistry Guideline on Antibiotic Prophylaxis for Dental Patients at Risk for Infection Originating Committee clinical affairs committee Review Council council on clinical affairs Adopted 1990 Revised 1991, 1997, 1999, 2002, 2005, 2007, 2008 Purpose may be at increased risk. If a patient reports a syndrome or The American Academy of Pediatric Dentistry (AAPD) recog- medical condition with which the practitioner is not familiar, nizes that numerous medical conditions predispose patients it is appropriate to contact the child’s physician to determine to bacteremia-induced infections. Because it is not possible to susceptibility to bacteremia-induced infections. predict when a susceptible patient will develop an infection, In 2007, the American Heart Association (AHA) released its prophylactic antibiotics are recommended when these patients newly revised guidelines for the prevention of IE and reducing undergo procedures most likely to produce bacteremia. This the risk for producing resistant strains of bacteria.3 The 2007 guideline is intended to help practitioners make appropriate revision was based on relevant literature and studies, in con- decisions regarding antibiotic prophylaxis for dental patients sultation with national and international experts. The AAPD, at risk. acknowledging the AHA’s expertise and efforts to produce evidenced-based recommendations, continues to endorse the Methods AHA guideline for antibiotic prophylaxis, now entitled “Pre- This guideline is based on a review of current dental and medical vention of Infective Endocarditis”. literature pertaining to postprocedural bacteremia-induced The primary reasons for the revision include: infections. A MEDLINE search was performed using the key- • “IE is much more likely to result from frequent exposure words “infective endocarditis” (IE), “bacteremia”, “antibiotic to random bacteremias associated with daily activities than prophylaxis”, and “dental infection”. -
Antibiotic Prophylaxis for GI Endoscopy
GUIDELINE Antibiotic prophylaxis for GI endoscopy This is one of a series of statements discussing the use of procedure. Endoscopy-related bacteremia carries a small GI endoscopy in common clinical situations. The Stan- risk of localization of infection in remote tissues (ie, infec- dards of Practice Committee of the American Society for tive endocarditis [IE]). Endoscopy also may result in local Gastrointestinal Endoscopy (ASGE) prepared this docu- infections in which a typically sterile space or tissue is ment, and it updates a previously issued document on breached and contaminated by an endoscopic accessory this topic.1 In preparing this guideline, MEDLINE and or by contrast material injection. This document is an up- PubMed databases were used to search for publications date of the prior ASGE document on antibiotic prophylaxis between January 1975 and December 2013 pertaining for GI endoscopy,1 discusses infectious adverse events to this topic. The search was supplemented by accessing related to endoscopy, and provides recommendations for the “related articles” feature of PubMed, with articles periprocedural antibiotic therapy. identified on MEDLINE and PubMed as the references. Additional references were obtained from the bibliogra- phies of the identified articles and from recommenda- BACTEREMIA ASSOCIATED WITH tions of expert consultants. When few or no data were ENDOSCOPIC PROCEDURES available from well-designed prospective trials, emphasis was given to results from large series and reports from Bacteremia can occur after endoscopic procedures and has been advocated as a surrogate marker for IE risk. How- recognized experts. Weaker recommendations are indi- fi cated by phrases such as “We suggest.” whereas stronger ever, clinically signi cant infections are extremely rare. -
Antibiotic Resistance: Nosopharm and the University of Illinois at Chicago Describe Mechanism of Action of New Class of Antibiotics in Molecular Cell
Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell Newly discovered antibiotic binds to ribosome and disrupts protein synthesis Lyon, France, and Chicago (IL), United States - April 5 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and the University of Illinois at Chicago (UIC) today announce the publication of a study in Molecular Cell on the mechanism of action of odilorhabdins, a new class of antibiotics to combat antibiotic resistance. The antibiotic, first identified by Nosopharm, is unique and promising on two fronts: its unconventional source and its distinct way of killing bacteria, both of which suggest the compound may be effective at treating drug-resistant or hard to treat bacterial infections. Called odilorhabdins, or ODLs, the antibiotics are produced by symbiotic bacteria found in soil-dwelling nematode worms that colonize insects for food. The bacteria help to kill the insect and, importantly, secrete the antibiotic to keep competing bacteria away. Until now, these nematode-associated bacteria and the antibiotics they make have been largely understudied. The odilorhabdin program was launched by Nosopharm in 2011. To identify the antibiotic, Nosopharm’s researchers team screened eighty cultured strains of the bacteria for antimicrobial activity. They then isolated the active compounds, studied their chemical structures and their structure-activity relationships, investigated their pharmacology and engineered more potent derivatives. The study, published in Molecular Cell1, describes the new antibiotic and, for the first time, how it works. Nosopharm’s Maxime Gualtieri, UIC's Alexander Mankin and Yury Polikanov are corresponding authors on the study and led the research on the antibiotic's mechanism of action. -
Antibiotic Prophylaxis for Surgical Procedures: a Scoping Review
01 Pan American Journal Review of Public Health 02 03 04 05 06 Antibiotic prophylaxis for surgical procedures: 07 08 a scoping review 09 10 11 1,2 2 1 2 2 Eva Brocard, Ludovic Reveiz, Jean-Philippe Régnaux, Veronica Abdala, Pilar Ramón-Pardo, 12 and Ana del Rio Bueno2 13 14 15 16 Suggested citation Brocard E, Reveiz L, Régnaux J-P, Abdala V, Ramón-Pardo P, del Rio Bueno A. Antibiotic prophylaxis for surgical procedures: 17 a scoping review. Rev Panam Salud Publica. 2021;45:e62. https://doi.org/10.26633/RPSP.2021.62 18 19 20 21 ABSTRACT Objectives. To map the current evidence on surgical antibiotic prophylaxis (SAP) administration and identify 22 knowledge gaps in the literature available in this field. 23 Methods. The PubMed, Cochrane Library, Epistemonikos, and Health Systems Evidence databases were 24 searched from January 2015 to March 2020 for systematic reviews published in English, French, Portuguese, 25 and Spanish. 26 Results. Eighty-three systematic reviews were included, the quality of the reviews was assessed using 27 AMSTAR 2, and data were extracted for all primary outcomes. Perioperative antibiotic administration, the use 28 of first generation cephalosporins, and surgical site infection (SSI) were the most commonly reported for timing 29 of antibiotic administration, drug class, and primary outcome, respectively. Findings showed that, overall, SAP 30 may reduce SSIs compared with a placebo or with no SAP. Results suggested that intraoperative SAP may 31 lower SSI, while postoperative SAP did not show a statistically significant difference. 32 Conclusions. Findings have confirmed the role of SAP in reducing postoperative SSI across various surgeries 33 and do not support the use of antibiotics after surgery to prevent infections. -
Polymyxin B* Class: Polymyxins Overview Polymyxin B Is a Polypeptide Bactericidal Antibiotic. the Polymyxins Were Discovered In
Polymyxin B* Class: Polymyxins Overview Polymyxin B is a polypeptide bactericidal antibiotic. The polymyxins were discovered in 1947 and introduced to the medical community in the 1950s. Colistin, also called polymyxin E and its parenteral form, colistimethate, are related polymyxins. Polymyxins can be administered orally, topically or parenterally, including intrathecally and intraperitoneally. However parenteral administration is primarily used in life threatening infections caused by Gram-negative bacilli or Pseudomonas species that are resistant to other drugs. Polymyxins exert their effect on the bacterial cell membrane by affecting phospholipids and interfering with membrane function and permeability, which results in cell death. Polymyxins are more effective against Gram-negative than Gram- positive bacteria and are effective against all Gram-negative bacteria except Proteus species. These antibiotics act synergistically with potentiated sulfonamides, tetracyclines and certain other antimicrobials. Polymyxins also limit activity of endotoxins in body fluids and therefore, may be beneficial in therapy for endotoxemia. Polymyxins are not well absorbed into the blood after either oral or topical administration. Polymyxins bind to cell membranes, purulent exudates and tissue debris. The drugs are eliminated from the kidneys with approximately sixty percent of polymyxin B and ninety percent of colistin excreted unchanged. Polymyxins are considered nephrotoxic and neurotoxic and neuromuscular blockade is seen at higher concentrations. In reality, the potential for nephrotoxicity is minimal when the drugs are utilized properly, especially colistin. Polymyxin B is a potent releaser of histamines and hypersensitivity reactions can occur. Parenteral polymyxins are often characterized by intense pain at the injection site. Divalent cations, unsaturated fatty acids and quaternary ammonium compounds inhibit the activity of polymyxins. -
Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.